Adapting versatile
polymers to improve
surgical outcomes
and patient recovery

Press Releases

17 April 2014

Polyganics obtains CE approval to market NASOPORE-FD®

Groningen, the Netherlands, 17 April 2014 – Polyganics today announces the CE regulatory approval of NASOPORE- FD®, a sinunasal dressing with a rapid clearance time. NASOPORE-FD® is the latest addition to Polyganics’ front-running bioresorbable nasal dressing portfolio marketed under the NASOPORE® brand. After insertion, NASOPORE-FD® exerts moderate elastic compression on the surrounding tissue for 36-48 hours while absorbing surrounding fluids.

This is an important milestone in the extension of our successful NASOPORE® product family”, says Rudy Mareel, CEO of Polyganics. “We believe the unique characteristics of NASOPORE-FD® offer a valuable new option to doctors.”

About Polyganics

Polyganics is a medical technology company with multiple versatile polymer platforms. The Company develops, manufactures and commercializes innovative bioresorbable medical devices that facilitate tissue repair and regeneration.

The existing portfolio includes products developed in-house and in collaboration with leading medical technology companies and academic centers of excellence. Surgical applications include peripheral nerve repair, neuro-, general, as well as ear, nose & throat surgery.

Polyganics is profitable, privately held, and based in Groningen, The Netherlands, a center of biomedical engineering excellence. The Company’s polymer platform technologies are protected by a broad portfolio of patents.

For more information, please visit www.polyganics.com